[go: up one dir, main page]

US20070088032A1 - Processes for the Preparation of Benzoimidazole Derivatives - Google Patents

Processes for the Preparation of Benzoimidazole Derivatives Download PDF

Info

Publication number
US20070088032A1
US20070088032A1 US11/567,071 US56707106A US2007088032A1 US 20070088032 A1 US20070088032 A1 US 20070088032A1 US 56707106 A US56707106 A US 56707106A US 2007088032 A1 US2007088032 A1 US 2007088032A1
Authority
US
United States
Prior art keywords
alkyl
process according
cycloalkyl
formula
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/567,071
Inventor
Norma Tom
David Ripin
Michael Castaldi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US11/567,071 priority Critical patent/US20070088032A1/en
Publication of US20070088032A1 publication Critical patent/US20070088032A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

  • This invention relates to novel processes for preparing benzimdazole deriatives that are useful in the treatment of abnormal cell growth, such as cancer, in mammals.
  • This invention also relates to novel processes for preparing intermediates that may be converted to the aforementioned benzimidazole derivatives.
  • Benzimidazole derivatives, intermediates useful in preparing such bezimidazole derivatives and processes for preparing such benzimidazole derivatives and intermediates have been disclosed in Interational Patent Publication WO 01/40217 published Jun. 7, 2001, and U.S. Provisional Patent Applicatton Ser. Nos. 60/406,524, and 60/417,047, filed Aug. 28, 2002, and Oct. 28, 2002 respectively.
  • the present invention relates to a process for preparing a compound of the formula I or a pharmaceutically acceptable salt, prodrug, hydrate or solvate thereof; wherein each R 1 , R 2 , and R 3 is independently selected from the group consisting of H, (C 1 -C 6 )alkl, (C 3 -C 8 ) cycloalkyl, halo, cyano, CF 3 difluoromethoxy, trifluoromethoxy, —O(C 1 -C 6 )alkyl, —O(C 3 -C 8 ) cycloalkyl, and —NR 12 R 13 ;
  • R 4 is —(CR 5 R 8 ) m H, or —(CR 7 R 8 ) m (4 to 10 membered)-araornatic or nonaromatic beterocyclic containing one or more heteroatoms each seleoted fom O, S and N, wherein m is an integer ranging from 1 to 5, wherein n is an integer ranging from 0 to 5, wherein said 4 to 10 membered heterocyolic when aromatic is optionally substituted by 1 to 3 R 8 substituents, and wherein said 4 to 10 membered heterocyclic when non-aromatic is optionally substitled by 1 to 3 R 10 substituents at any position and optionally substituted by 1 to 3 R 11 substituents at any position not adjacent to or directly attached to a heteroatom;
  • each R 5 , R 6 , R 7 and R 8 is independently selected from the group consisting of H and (C 1 -C 6 )alkyl, such as methyl, ethyl, propyl, butyl and pentyl;
  • each R 9 is independently selected from H, (C 1 -C 6 )alkyl, such as methyl, ethyl, propyl, butyl and pentyl, (C 3 -C 6 )cycloalkyl, halo, cyano, CF 3 , difluoromethoxy, trifluoromethoxy, —O(C 1 -C 6 )alkyl, —O(C 3 C 6 )cycloalkyl, and —NR 14 R 15 ,
  • each R 10 is independently selected from H, (C 1 -C 10 )alkyl, and (C 3 -C 6 )cycloalkyl;
  • each R 11 is independently selected from halo, cyano, CF 3 , difluoromethoxy, trifluoromethoxy, —O(C 1 -C 6 )alkyl, —O(C 3 -C 6 )cycloalkyl, and —NR 16 R 17 ;
  • each R 12 , R 13 , R 14 , R 15 , R 16 and R 17 is independently selected from the group consisting of H, (C 1 -C 6 )alkyl, and (C 3 -C 6 )cycloalkyl;
  • each of the aforesaid (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, —O(C 1 -C 6 )alky and —O(C 3 -C 6 )cycloalkyl substituents wherever they occur may optionally be independently substituted by one to three substituents independently selected from the group consisting of halo, cyano, amino, (C 1 -C 6 )alkylamino, [(C 1 -C 6 )alkyl] 2 -amino, perhalo(C 1 -C 6 )alkyl, perhalo(C 1 -C 6 )alkoxy, (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alknyl, hydroxy, and (C 1 -C 6 )alkoxy, comprsing reacting a compound of the formula II wherein BOC is cyan
  • the water is present in an amount of about one equivalent (i.e., one equivalent with respect to the compound of formula II).
  • the alkaline earth metal alkoxide is preferably an alkaline earth metal (C 1 -C 6 )alkoxide.
  • the alkaline earth metal is is preferably sodium or potassium, and the (C 1 -C 6 )alkoxide is preferably t-butoxide,
  • the reaction is preferably conducted in the presence of a solvent, such as an ether.
  • a solvent such as an ether.
  • the ether is preferably a cyclic ether, although acyrlic ethers may also be used, Examples of suitable ethers include dioxane, dimetnoxynethane, diethoxymethane, tetrahydrofuran and 2-methyl tetrahydrofuran, or mixtures of at least two thereof. Tetrahytrofuran, 2-methyltetrahydrofuran or mixtures thereof are especially preferred.
  • the reaction is conducted at a temperature of about 50° C. to about 110° C., and in a more preferable embodiment at a temperature of about 60° C. to about 80° C.
  • An embodiment of the present invention refers to thoses processes wherein the 4 to 10 membered heterocyclic is a 4 to 8 membered heterocylic, in another embodiment a 4 to 6 membered heterocyclic, in another embodiment a 6-membered heterocyclic in another embodiment a 5-membered heterocyclic and in another embodiment a 4-membered heterocyclic.
  • Another embodiment of the present invention refers to thoses processes wherein m is an integer from 1 to 5, in another embodiment 1, and in another embodiment 2.
  • Another embodiment of the present invention refers to those processes wherein n is an integer from 0 to 5, in another embodiment 1, and in another embodiment 2.
  • Another embodiment of the present invention refers to thoses processes wherein when the 4 to 10 membered heterocyclic is aromatic, it may be optionally substituted by 1 R 9 substituent.
  • An embodiment of the present invention refers to thoses processes wherein the 4 to 10 membered heterocyclic group is an aromatic heterocyclic group.
  • suitable of such aromatic hetercyclic groups include, pyridinyl pyrimidinyl, pyrazinyl, quinolinyl, isoquinolinyl, pyrrolyl, pyrazoyll, imidazolyl, thiophenyl, furanyyl, indolyl and benzofuranyl.
  • Another embodiment of the present invention refers to those processes wherein the the 4 to 10 membered hetercyclic group is a non-aromatic heterocyclic group.
  • suitable non-aromatic heterocyclic groups include tetrahydrothiopranyl thiomorpholino, dioxanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropytranyl, piperidino, morpholino, piperazinyl, homopiperazinyl, azetidinyl, oxetanyl, homopiperidinyl, 3-azabicyco[3.1.0hexanyl, 3-azabicyclo[4.1.0]heptanyl, azabicycto[2.2.2]hexanyl, 3H-indolyl, and 4H-pyranyl.
  • Another embodiment of the present invention refers to those processes wherein the 4 to 10 membered aromatic heterocyclic group containing one or more heteroatoms each selected from O, S and N contains one to four heteroatoms each selected from O, S and N, with the proviso that said 4 to 10 membered aromatic heterocyclic does not contain two adjacent O or S atoms,
  • the 4 to 10 membered hetercyclic group contains one to two O atoms, and in another embodiment one O atom.
  • the 4 to 10 membered hetercylic group contains one to two N atoms, and in a preferred embodiment one N atom.
  • Another embodiment of the present invention refers to those processes wherein the compound of formula I is selected from the group consisting of 1- ⁇ 2-[5-(3-Morpholin4-yl-propoxy)-benzoimidazol1-yl-quinolin-8-yl-piperidin4-ylamine;
  • the present invention refers to those processes wherein the compound of formula I is the benezenesulfonate salt of 1- ⁇ 2-[5-(3-Methyl-oxetan-3-ylmethoxy)benzoimidazol-1-yl]-quinolin-8-yl ⁇ -piperidin-4-ylamine.
  • the present invention also relates to a process for preparing a compound of formula wherein Bn is benzyl and wherein R 1 , R 2 , R 3 and R 4 are as defined above for formula I; comprising reacting a compound of formula VII wherein R 3 and R 4 are as defined above for formula I, with a compound of formula VIII wherein R 1 and R 2 are as defined above for formula I, in the presence of 1,2-Bis(diphenylphosphino)ethane, a base and a a palladium catalyst, such as a palladium (0) or a palladium (II) catalyst.
  • a palladium catalyst such as a palladium (0) or a palladium (II) catalyst.
  • the palladium catalyst is preferably tri(dibenzylidene acetone) dipailadium (0) or palladium acetate, with the latter being most preferred.
  • suitable bases include potassium phosphate, sodium t-butoxide and cesium carbonate.
  • One especially preferred embodiment of the present invention refers to those processes wherein the palladium catalyst is palladium acetate, and the base is cesium carbonate.
  • the reaction is preferably carried out in the presence of an aromatic solvent, such as toluene, an ether, such as dioxane, dimethoxyethane, or tetrahydrofuran, or a polar nitrogen-containing solvent such as dimethylformamide (DMF). Solvent mixtures can also be used.
  • the reaction may be carried out at a temperature of of about 90° C. to about 120° C.
  • An especially preferred embodiment of the present invention refers to those processes wherein R 1 and R 2 in the compound of formula VIII are both hydrogen, and the compound of formula VII is a compound of formula VIIA
  • the compound of formula VI is useful as an intermediate toward the preparation of the compounds of formrula I.
  • halo as used herein, unless otherwise indicated, includes fluoro, chloro, bromo or iodo. Preferred halo groups are fluoro and chloro.
  • alkyl as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight or branched moieties. It is understood that for said alkyl group to include cyclic moieties it must contain at least three carbon atoms.
  • cycloalkyl as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having cyclic (incuding mono or multicyclic) moieties.
  • alkenyl as used herein, unless otherwise indicated, includes alkyl groups, as defined above, having at least one carbon-carbon double bond.
  • alkynyl as used herein, unless otherwise indicated includes alkyl groups, as defined above, having at least one carbon-carbon triple bond.
  • alkoxy as used herein, unless otherwise indicated, includes alkyl groups wherein alkyl is as defined above.
  • solvate includes, a compound of the invention or a salt thereof, that further includes a stoichiometric or non-stoichiornetric amount of a solvent bound by non-covalent intermolecular forces.
  • Preferred solvents are volatile, non-toxic, and/or acceptable for topical administration to humans.
  • hydrate refers to a compound of the invention or a salt thereof, that further includes a stoichiometric or non-stoichiometric amount of water bound by non-covalent intermolecular forces.
  • 4 to 10 membered heterocyclic includes aromatic and non-aromatic heterocyclic groups containing one or more heteroatoms each selected from O, S and N, wherein each heterocyclic group has fron 4 to 10 atoms in its ring system.
  • Non-aromatic heterocyclic groups include groups having only 4 atoms in their ring system, but aromatic heterocyclic groups must have at least 5 atoms in their ring system.
  • the heterocyclic groups include benzo-fused ring systems and ring systems substituted with one or more oxo moieties.
  • An example of a 4 membered heterocyclic group is azetidinyl (derived from azetidine).
  • An example of a 5 membered heterocyclic group is thiazolyl and an example of a 10 membered heterocyclic group is quinolinyl.
  • Examples of non-aromatic heterocyclic groups are pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, azetidinyl, oxetanyl, thietanytl, homopiperdinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyndinyl, 2-pyrrolinyl, 3-pyrroiniyl, indolinyl, 2H-pyranyl, 4H
  • aromatic heterocyclic groups are pyridinyl, imidazolyl, pyrimidiny, pyrazilyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinoliny, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazoyl, indolizinyl, phthaelazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, beinzothiazolyl, benzoxazolyl, quinazolinyl,
  • Spiro moieties are also included within the scope of this definition including 1-oxa-6-aza-spiro2.5]oct-6-yl.
  • the foregoing groups may be C-attached or N-attached where such is possible.
  • a group derived from pyrole may be pyrrol-1-yl (N-attached) or pyrrol3-yl (C-attached).
  • a group derived from imidazole may be imidazo1-yl (N-attached) or imidazoi-3-yl (C-attached).
  • phrases “pharmraceutically acceptable sat(s), as used herein, unless otherwise indicated, includes salts of acidic or basic groups which may be present in the compounds of formula I.
  • the compounds of formula I that are basic in nature are capable of forming a wide variety of salts with a rious inorganic and organic acids.
  • the acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds of formula I are those that form non-toxic acid addition salts, i.e.
  • salts containing pharmacologically acceptable anions such as the acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, catcium edetate, camsytate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edistyate, estolate, esylate, ethysuccinate, fumarate.
  • prodrugs of the compounds of the formula I are functional derivativatives of the compounds of formula I which are readily convertible convertible in vivo into the required compound of formula I.
  • Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in “Design of Prodrugs”, ed. H. Bundgaard, Elsevier, 1985.
  • a prodrug may be a pharmacologically inactive derivative of a biologically active substance (the “parent drug” or “parent molecule”) that requires transformation within the body in order to release the active drug, and that has improved delivery properties over the parent drug molecule.
  • the transformation in vivo may be, for example, as the result of some metabolic process, such as chemical or enzymatic hydrolysis of a carboxytic, phosphoric or sulphate ester, or reduction or oxidation of a susceptible functionalty.
  • Prodrugs include compounds wherein an amino acid residue, or a polypeptide chain of two or more (e .g, two, three or four) amino acid residues is covalently joined through an amide or ester bond to a free amino, hydroxy or carboxylic acid group of compounds of the present invention.
  • the amino acid residues include but are not limited to the 20 naturally occurring amino acids commonly designated by three letter symbols and also includes 4-hydroxyprolilne, hydroxylysine, demosine, isodernosine, 3-methylhistidine, norvalin, beta-alanine, gamma-aminobutyric acid, citrutline homocysteine, homoserine, ornithine and methionine sulfone. Additional types of prodrugs are also encompassed. For instance, free carboxy groups can be derivatized as amides or alkyl esters.
  • Free hydroxy groups may be derivatized using groups including but not limited to hemisuccinates, phosphate esters, dimethylaminoacetates, and phosphoryloxymethyloxycarbonyls, as outlined in “ Advanced Drug Delivery Reviews, 1996, 19, 115.
  • Carbamate prodrugs of hydroxy and amino groups are also included, as are carbonate prodrugs, suffonate esters and sulfate esters of hydroxy groups.
  • acyl group may be an alkyl ester, optionally substituted with groups including but not limited to ether, amine and carboxylic acid functionalities, or where the acyl group is an amino acid ester as described above, are also encompassed.
  • Prodrugs of this type are described in J. Med. Chem. 1996, 39, 10. Free amines can also be derivatized as amides, sulfonamides or phosphonamides. All of these prodrug moieties may incorporate groups including but not limited to ether, amine and carboxylic acid functionalities.
  • the compounds referred to in the processes of the present invention may have one or more asymmetric centres, and may accordingly exist both as enantiormers and as diastereolsomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of such ccmpounds.
  • Certain compounds of formula I may have asymmetric centers and therefore exist in different enantiomeric forms, All optical isomers and stereoisomers of the compounds of formula I, and mixtures thereof, are considered to be within the scope of the compounds of formula I.
  • the compounds of formula I may include a racemate, one or more enantiomeric forms, one or more diastereomeric forms, or mixtures thereof.
  • the compounds of formula I may also exist as tautomers. Reference to the compound of formula I includes reference to the use of all such tautomers and mixtures thereof.
  • Me means methyl
  • Et means ethyl
  • Ac means acetyl
  • DMF dimethyformamide
  • NMP N-methypyrrolidinone (also known as 1-Methyl-2-pyrrolidinone ⁇ .
  • DIPHOS 1, 2-Bis(diphenylphosphino)ethane
  • BINAP[ (abbreviation for 2,2′-Bis(diphenylphosphino)-1,1′-binaphthyl), as used herein, unless otherwise indicated, is represented by the following formula:
  • the compounds referred to in the processes of the present invention also include isotopically-labelled compounds, which are identical to compounds referred to herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitroen, oxygen, phosphorous, fluorine and chlorine, such as 2H, 3 H, 13 C, 14 C, 15 N, 18 O, 17 O, 31 P, 32 P, 35 S, 18 F, and 38 Cl, respectively.
  • Isotopically labelled compounds of Formula I of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples and Preparations below, by substituting a readily available isotopically labelled reagent for a non-isotopically labelled reagent.
  • the compond of formula I may be prepared starting with the palladium amination of reaction of a 2chloro-8-benzyloxyquinoline (VIII) and an appropriate 2-amino-nitrobenzene (VII) to provide the quinoline (VI).
  • Reduction of the nitro group and removal of the benzyl group via cataytic hydrogenation, followed by addition of formamidine acetate provides the benzimidazole (V) which can then be transformed into the corresponding trifiate (IV).
  • a second palladium catalyzed amination With amine (III) provides piperidinyl quinoline (II) and subsequent removal of the t-butoxycarbonyl group provides (I).
  • the reaction of the compound of formula VIII with the compound of formula VII in the presence of palladium acetate and DIPHOS (1, 2-Bis(diphenylphosphino)ethane ⁇ to produce the compound of formula VI is particularly and unexpectedly advantageous compared to the same reaction using palladium acetate, BINAP and PhB(OH) 2 .
  • the reaction in the presence of DIPHOS results in higher (e.g., 5-25% higher) yields of the product and takes less time to go to completion, particularly in high scale (e.g., 100 grams and higher) synthesis. This process has significant commercial advantages for the production of active ingredients for use in the preparation of a drug.
  • pressure is not critical unless otherwise indicated. Pressures from about 0.5 atmospheres to about 5 atmospheres are generally acceptable, and ambient pressure i.e., about 1 atmosphere, is preferred as a matter of convenience.
  • HPLC chromatography is referred to in the preparations and examples below, the general conditions used, unless otherwise indicated, are as follows.
  • the column used is a ZORBAX RXC18 column (manufactured by Hewlett Packard) of 150 mm distance and 4.6 mm interior diameter.
  • the samples are run on a Hewlett Packard-1100 system.
  • a gradient solvent method is used running 100 percent ammonium acetate/acetic acid buffer (0.2 M) to 100 percent acetonitrile over 10 minutes.
  • the system then proceeds on a wash cycle with 100 percent acetonitrile for 1.5 minutes and then 100 percent buffer solution for 3 minutes.
  • the flow rate over this period is a constant 3 mL/minute.
  • the flask and the filter cake were rinsed with 2 by 6 volumes of ethyl acetate.
  • the filtrate was then washed with 25 volumes of 0.5 N sodium hydroxide solution, followed by 25 volumes of saturated sodium chloride solution.
  • the resulting solution was concentrated to low volume and isopropanol (25 mL, 5 volumes) was added.
  • the solids were granulated at 20-25° C. for at least 10 hours and then collected and dried under vacuum at 40° C. with a slight nitrogen bleed to provide 7.7 g of a reddish orange fluffy solid (74% yield).
  • N-Phenyftrifluoromethanesulfonimide (PhN(Tf) 2 , 2.72 g, 7.6 mmol, 1.1 equivalents), 2-[5-(3-Methyl-oxetan-3-ylmethoxy)-benzoimidazol-1-yl]-)quinolin-8-ol (2.5 g, 6.9 mmol, 1.0 equivalent), DMF (7.5 mL, 3 volumes), and then triethylamine (1.9 mL, 13.8 mmol, 2.0 equivalents) were charged to a 50 mL round bottom flask. The slurry was stirred at 20-30° C. for 20-10 hours.
  • BiNAP (379 mg, 608 ⁇ mol, 0.06 equivalents), tris ⁇ dibenzyideneacetone)dipalladium (186 mg, 203 ⁇ mol, 0.02 equivalents) and toluene (35 mL, 7 volumes) were added to a 100 mL round bottom flask. The solution was dieoxygenated and stirred at 20-25° C. for ⁇ 30 minutes.
  • reaction completion the mixture was cooled to 20-30° C., The reaction was quenched into a 20% citric acid solution (10 volumes) and stirred at 20-30° C. for 30-60 minutes. The citrate salt precipitated out of solution during this time.
  • a 50% sodium hydroxide solution ( ⁇ 1 weight equivalent) was charged to basify the reaction mixture (pH 10-12). The layers were separated at 30-40° C. The aqueous layer was washed with ethyl acetate (10 volumes) and then the combined organic were concentrated to low volume. Ethyl acetate (14 mL, 7 volumes) was charged and the slurry was allowed to granulate for 10-20 hours.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epoxy Compounds (AREA)

Abstract

The present invention relates to a process for preparing a compound of the formula I
Figure US20070088032A1-20070419-C00001
or a pharmaceutically acceptable salt, prodrug, hydrate or solvate thereof. wherein R1, R2, R3 and R4 are as defined herein. The compound of formula I is useful in the treatment of abnormal cell growth, such as cancer in mammals.

Description

    BACKGROUND OF THE INVENTION
  • This invention relates to novel processes for preparing benzimdazole deriatives that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to novel processes for preparing intermediates that may be converted to the aforementioned benzimidazole derivatives. Benzimidazole derivatives, intermediates useful in preparing such bezimidazole derivatives and processes for preparing such benzimidazole derivatives and intermediates have been disclosed in Interational Patent Publication WO 01/40217 published Jun. 7, 2001, and U.S. Provisional Patent Applicatton Ser. Nos. 60/406,524, and 60/417,047, filed Aug. 28, 2002, and Oct. 28, 2002 respectively.
    • SUMMARY OF THE INVENTION
  • The present invention relates to a process for preparing a compound of the formula I
    Figure US20070088032A1-20070419-C00002
    or a pharmaceutically acceptable salt, prodrug, hydrate or solvate thereof; wherein each R1, R2, and R3 is independently selected from the group consisting of H, (C1-C6)alkl, (C3-C8) cycloalkyl, halo, cyano, CF3difluoromethoxy, trifluoromethoxy, —O(C1-C6)alkyl, —O(C3-C8) cycloalkyl, and —NR12R13;
  • wherein R4 is —(CR5R8)mH, or —(CR7R8)m(4 to 10 membered)-araornatic or nonaromatic beterocyclic containing one or more heteroatoms each seleoted fom O, S and N, wherein m is an integer ranging from 1 to 5, wherein n is an integer ranging from 0 to 5, wherein said 4 to 10 membered heterocyolic when aromatic is optionally substituted by 1 to 3 R8 substituents, and wherein said 4 to 10 membered heterocyclic when non-aromatic is optionally substitled by 1 to 3 R10 substituents at any position and optionally substituted by 1 to 3 R11 substituents at any position not adjacent to or directly attached to a heteroatom;
  • wherein each R5, R6, R7 and R8 is independently selected from the group consisting of H and (C1-C6)alkyl, such as methyl, ethyl, propyl, butyl and pentyl;
  • wherein each R9 is independently selected from H, (C1-C6)alkyl, such as methyl, ethyl, propyl, butyl and pentyl, (C3-C6)cycloalkyl, halo, cyano, CF3, difluoromethoxy, trifluoromethoxy, —O(C1-C6)alkyl, —O(C3C6)cycloalkyl, and —NR14R15,
  • wherein each R10 is independently selected from H, (C1-C10)alkyl, and (C3-C6)cycloalkyl;
  • wherein each R11 is independently selected from halo, cyano, CF3, difluoromethoxy, trifluoromethoxy, —O(C1-C6)alkyl, —O(C3-C6)cycloalkyl, and —NR16R17;
  • wherein each R12, R13, R14, R15, R16 and R17 is independently selected from the group consisting of H, (C1-C6)alkyl, and (C3-C6)cycloalkyl;
  • wherein each of the aforesaid (C1-C6)alkyl, (C3-C6)cycloalkyl, —O(C1-C6)alky and —O(C3-C6)cycloalkyl substituents wherever they occur may optionally be independently substituted by one to three substituents independently selected from the group consisting of halo, cyano, amino, (C1-C6)alkylamino, [(C1-C6)alkyl]2-amino, perhalo(C1-C6)alkyl, perhalo(C1-C6)alkoxy, (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alknyl, hydroxy, and (C1-C6)alkoxy, comprsing reacting a compound of the formula II
    Figure US20070088032A1-20070419-C00003
    wherein BOC is t-butoxycarbonyl, and R1, R2, R3 and R4 are as defined above for the compound of formula I, with a metal alkoxide, preferably an alkaline earth metal in the presence of water to give a compound of the formula I. Preferably, the water is present in an amount of about one equivalent (i.e., one equivalent with respect to the compound of formula II). The alkaline earth metal alkoxide is preferably an alkaline earth metal (C1-C6)alkoxide. The alkaline earth metal is is preferably sodium or potassium, and the (C1-C6)alkoxide is preferably t-butoxide,
  • The reaction is preferably conducted in the presence of a solvent, such as an ether. The ether is preferably a cyclic ether, although acyrlic ethers may also be used, Examples of suitable ethers include dioxane, dimetnoxynethane, diethoxymethane, tetrahydrofuran and 2-methyl tetrahydrofuran, or mixtures of at least two thereof. Tetrahytrofuran, 2-methyltetrahydrofuran or mixtures thereof are especially preferred. Preferably the reaction is conducted at a temperature of about 50° C. to about 110° C., and in a more preferable embodiment at a temperature of about 60° C. to about 80° C.
  • An embodiment of the present invention refers to thoses processes wherein the 4 to 10 membered heterocyclic is a 4 to 8 membered heterocylic, in another embodiment a 4 to 6 membered heterocyclic, in another embodiment a 6-membered heterocyclic in another embodiment a 5-membered heterocyclic and in another embodiment a 4-membered heterocyclic. Another embodiment of the present invention refers to thoses processes wherein m is an integer from 1 to 5, in another embodiment 1, and in another embodiment 2. Another embodiment of the present invention refers to those processes wherein n is an integer from 0 to 5, in another embodiment 1, and in another embodiment 2. Another embodiment of the present invention refers to thoses processes wherein when the 4 to 10 membered heterocyclic is aromatic, it may be optionally substituted by 1 R9 substituent.
  • An embodiment of the present invention refers to thoses processes wherein the 4 to 10 membered heterocyclic group is an aromatic heterocyclic group. Examples of suitable of such aromatic hetercyclic groups include, pyridinyl pyrimidinyl, pyrazinyl, quinolinyl, isoquinolinyl, pyrrolyl, pyrazoyll, imidazolyl, thiophenyl, furanyyl, indolyl and benzofuranyl.
  • Another embodiment of the present invention refers to those processes wherein the the 4 to 10 membered hetercyclic group is a non-aromatic heterocyclic group. Examples of suitable non-aromatic heterocyclic groups include tetrahydrothiopranyl thiomorpholino, dioxanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropytranyl, piperidino, morpholino, piperazinyl, homopiperazinyl, azetidinyl, oxetanyl, homopiperidinyl, 3-azabicyco[3.1.0hexanyl, 3-azabicyclo[4.1.0]heptanyl, azabicycto[2.2.2]hexanyl, 3H-indolyl, and 4H-pyranyl.
  • Another embodiment of the present invention refers to those processes wherein the 4 to 10 membered aromatic heterocyclic group containing one or more heteroatoms each selected from O, S and N contains one to four heteroatoms each selected from O, S and N, with the proviso that said 4 to 10 membered aromatic heterocyclic does not contain two adjacent O or S atoms, In a preferred embodiment, the 4 to 10 membered hetercyclic group contains one to two O atoms, and in another embodiment one O atom. In another embodiment, the 4 to 10 membered hetercylic group contains one to two N atoms, and in a preferred embodiment one N atom.
  • Another embodiment of the present invention refers to those processes wherein the compound of formula I is selected from the group consisting of 1-{2-[5-(3-Morpholin4-yl-propoxy)-benzoimidazol1-yl-quinolin-8-yl-piperidin4-ylamine;
  • (±)-1-{2-[5-(Tetrahydro-furan-3-3-yloxy)-benzoimidazol-1-quinolin-[-8-yl-}-piperidin-4-ylamine;
  • (+)-1-{2-[5-(Tetrahydro-furan3-yloxy)-benzoimidazol-1-yl]-quinolin-8-yl}-piperidin4-ylamine;
  • (−)-1-55 2 -[5-(Tetrahydro-furan-3-yloxy)-benzomidazol-1-yl]-quinolin-8-yl}-piperidin4-ylamine;
  • 1-{2-[5-(3-Methyl-oxetan-3-ylmethoxy)benzoimidazol-1-yl]-quinolin-8-yl}-piperidin-4-ylamine;
  • 1-{2-[5-(Tetrahdro-pyran-4-yloxy)-benzoimnidazol-1-yl]quinolin8-yl}-piperidin-4-ylarmine; and the pharmaceutically acceptable salts, prodrugs, hydrates and solvates of the foregoing compounds,
  • In an especially preferred embodiment, the present invention refers to those processes wherein the compound of formula I is the benezenesulfonate salt of 1-{2-[5-(3-Methyl-oxetan-3-ylmethoxy)benzoimidazol-1-yl]-quinolin-8-yl}-piperidin-4-ylamine.
  • The present invention also relates to a process for preparing a compound of formula
    Figure US20070088032A1-20070419-C00004
    wherein Bn is benzyl and wherein R1, R2, R3 and R4 are as defined above for formula I; comprising reacting a compound of formula VII
    Figure US20070088032A1-20070419-C00005
    wherein R3 and R4 are as defined above for formula I, with a compound of formula VIII
    Figure US20070088032A1-20070419-C00006
    wherein R1 and R2 are as defined above for formula I, in the presence of 1,2-Bis(diphenylphosphino)ethane, a base and a a palladium catalyst, such as a palladium (0) or a palladium (II) catalyst. The palladium catalyst is preferably tri(dibenzylidene acetone) dipailadium (0) or palladium acetate, with the latter being most preferred. Examples of suitable bases include potassium phosphate, sodium t-butoxide and cesium carbonate. One especially preferred embodiment of the present invention refers to those processes wherein the palladium catalyst is palladium acetate, and the base is cesium carbonate. The reaction is preferably carried out in the presence of an aromatic solvent, such as toluene, an ether, such as dioxane, dimethoxyethane, or tetrahydrofuran, or a polar nitrogen-containing solvent such as dimethylformamide (DMF). Solvent mixtures can also be used. The reaction may be carried out at a temperature of of about 90° C. to about 120° C.
  • An especially preferred embodiment of the present invention refers to those processes wherein R1 and R2 in the compound of formula VIII are both hydrogen, and the compound of formula VII is a compound of formula VIIA
    Figure US20070088032A1-20070419-C00007
  • The compound of formula VI is useful as an intermediate toward the preparation of the compounds of formrula I.
  • The term “halo”, as used herein, unless otherwise indicated, includes fluoro, chloro, bromo or iodo. Preferred halo groups are fluoro and chloro.
  • The term “alkyl”, as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight or branched moieties. It is understood that for said alkyl group to include cyclic moieties it must contain at least three carbon atoms.
  • The term “cycloalkyl ”, as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having cyclic (incuding mono or multicyclic) moieties.
  • The term “alkenyl”, as used herein, unless otherwise indicated, includes alkyl groups, as defined above, having at least one carbon-carbon double bond.
  • The term “alkynyl”, as used herein, unless otherwise indicated includes alkyl groups, as defined above, having at least one carbon-carbon triple bond.
  • The term “alkoxy”, as used herein, unless otherwise indicated, includes alkyl groups wherein alkyl is as defined above.
  • The term “solvate”, as used herein includes, a compound of the invention or a salt thereof, that further includes a stoichiometric or non-stoichiornetric amount of a solvent bound by non-covalent intermolecular forces. Preferred solvents are volatile, non-toxic, and/or acceptable for topical administration to humans.
  • The term “hydrate”, as used herein refers to a compound of the invention or a salt thereof, that further includes a stoichiometric or non-stoichiometric amount of water bound by non-covalent intermolecular forces.
  • The term “4 to 10 membered heterocyclic”, as used herein, unless otherwise indicated, includes aromatic and non-aromatic heterocyclic groups containing one or more heteroatoms each selected from O, S and N, wherein each heterocyclic group has fron 4 to 10 atoms in its ring system. Non-aromatic heterocyclic groups include groups having only 4 atoms in their ring system, but aromatic heterocyclic groups must have at least 5 atoms in their ring system. The heterocyclic groups include benzo-fused ring systems and ring systems substituted with one or more oxo moieties. An example of a 4 membered heterocyclic group is azetidinyl (derived from azetidine). An example of a 5 membered heterocyclic group is thiazolyl and an example of a 10 membered heterocyclic group is quinolinyl. Examples of non-aromatic heterocyclic groups are pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, azetidinyl, oxetanyl, thietanytl, homopiperdinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyndinyl, 2-pyrrolinyl, 3-pyrroiniyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxoanyl, pyrazolinyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinyl, imidazotinyl, imidazolidinyl, 3-azabicylo[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl, 3H-indolyl and quinolizinyl. Examples of aromatic heterocyclic groups are pyridinyl, imidazolyl, pyrimidiny, pyrazilyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinoliny, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazoyl, indolizinyl, phthaelazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, beinzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphtilyidinyl, and furopyridinyl. Spiro moieties are also included within the scope of this definition including 1-oxa-6-aza-spiro2.5]oct-6-yl. The foregoing groups, as derived from the groups listed above, may be C-attached or N-attached where such is possible. For instance, a group derived from pyrole may be pyrrol-1-yl (N-attached) or pyrrol3-yl (C-attached). Further, a group derived from imidazole may be imidazo1-yl (N-attached) or imidazoi-3-yl (C-attached). An example of a heterocyclic group wherein 2 ring carbon atoms are substituted with oxo (=O ) moieties is 1,1-dioxo-thiomorpholinyl.
  • The phrase “pharmraceutically acceptable sat(s), as used herein, unless otherwise indicated, includes salts of acidic or basic groups which may be present in the compounds of formula I. The compounds of formula I that are basic in nature are capable of forming a wide variety of salts with a rious inorganic and organic acids. The acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds of formula I are those that form non-toxic acid addition salts, i.e. salts containing pharmacologically acceptable anions, such as the acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, catcium edetate, camsytate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edistyate, estolate, esylate, ethysuccinate, fumarate. gluceptate, gluconate, glutamate, glycollylarsanilate, hexytresorcinate, trydrabamine, hydrobromide, hydrochloride, iodide, isothionate, lactate, lactobionate, laurate, malate, mateate, mandelate mesylate, methylsulfate, mucate, napsylate, nitrate, oleate, oxalate, pamoate (embonate), pamitate, pantothenate, phospataeldiphosphate, polygalacturonate, saliclate, stearate, subacetate, succinate, tannate, tartrate, teoclate, tosyate, triethiodode, and valerate salts. Since a single compound of the present invention may include more than one acidic or basic moieties, the compounds of the present invention may include mono, di or tri-salts in a single compound.
  • In general, “prodrugs” of the compounds of the formula I are functional derivativatives of the compounds of formula I which are readily convertible convertible in vivo into the required compound of formula I. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in “Design of Prodrugs”, ed. H. Bundgaard, Elsevier, 1985.
  • A prodrug may be a pharmacologically inactive derivative of a biologically active substance (the “parent drug” or “parent molecule”) that requires transformation within the body in order to release the active drug, and that has improved delivery properties over the parent drug molecule. The transformation in vivo may be, for example, as the result of some metabolic process, such as chemical or enzymatic hydrolysis of a carboxytic, phosphoric or sulphate ester, or reduction or oxidation of a susceptible functionalty.
  • Compounds referrred to in the processes of the present invention having free amino, amido, hydroxy or carboxylic groups can be converted into prodrugs. Prodrugs include compounds wherein an amino acid residue, or a polypeptide chain of two or more (e .g, two, three or four) amino acid residues is covalently joined through an amide or ester bond to a free amino, hydroxy or carboxylic acid group of compounds of the present invention. The amino acid residues include but are not limited to the 20 naturally occurring amino acids commonly designated by three letter symbols and also includes 4-hydroxyprolilne, hydroxylysine, demosine, isodernosine, 3-methylhistidine, norvalin, beta-alanine, gamma-aminobutyric acid, citrutline homocysteine, homoserine, ornithine and methionine sulfone. Additional types of prodrugs are also encompassed. For instance, free carboxy groups can be derivatized as amides or alkyl esters. Free hydroxy groups may be derivatized using groups including but not limited to hemisuccinates, phosphate esters, dimethylaminoacetates, and phosphoryloxymethyloxycarbonyls, as outlined in “Advanced Drug Delivery Reviews, 1996, 19, 115. Carbamate prodrugs of hydroxy and amino groups are also included, as are carbonate prodrugs, suffonate esters and sulfate esters of hydroxy groups. Derivatization of hydroxy groups as (acyloxy)methyl and (acytoxy)ethyl ethers wherein the acyl group may be an alkyl ester, optionally substituted with groups including but not limited to ether, amine and carboxylic acid functionalities, or where the acyl group is an amino acid ester as described above, are also encompassed. Prodrugs of this type are described in J. Med. Chem. 1996, 39, 10. Free amines can also be derivatized as amides, sulfonamides or phosphonamides. All of these prodrug moieties may incorporate groups including but not limited to ether, amine and carboxylic acid functionalities.
  • The compounds referred to in the processes of the present invention may have one or more asymmetric centres, and may accordingly exist both as enantiormers and as diastereolsomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of such ccmpounds. Certain compounds of formula I may have asymmetric centers and therefore exist in different enantiomeric forms, All optical isomers and stereoisomers of the compounds of formula I, and mixtures thereof, are considered to be within the scope of the compounds of formula I. The compounds of formula I may include a racemate, one or more enantiomeric forms, one or more diastereomeric forms, or mixtures thereof. The compounds of formula I may also exist as tautomers. Reference to the compound of formula I includes reference to the use of all such tautomers and mixtures thereof.
  • The term “Me” means methyl, “Et” means ethyl, and “Ac” means acetyl,
  • The term “DMF”, as used herein, unless otherwise indicated, means dimethyformamide.
  • The term “NMP”, as used herein, unless otherwise indicated, means N-methypyrrolidinone (also known as 1-Methyl-2-pyrrolidinone}.
  • The acronym “DIPHOS”, as used herein, unless otherwise indicated, refers to 1, 2-Bis(diphenylphosphino)ethane
  • The term “BINAP[ (abbreviation for 2,2′-Bis(diphenylphosphino)-1,1′-binaphthyl), as used herein, unless otherwise indicated, is represented by the following formula:
    Figure US20070088032A1-20070419-C00008
  • The compounds referred to in the processes of the present invention also include isotopically-labelled compounds, which are identical to compounds referred to herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitroen, oxygen, phosphorous, fluorine and chlorine, such as 2H, 3H, 13C, 14C, 15N, 18O, 17O, 31P, 32P, 35S, 18F, and 38Cl, respectively. Compounds referred to in the present invention, prodrugs thereof, and pharmaceutically acceptable salts of said compounds or of said prodrugs which contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of such compounds. Certain isotopically-labelled compounds referred to in the present invention, for example those into which radioactive isotopes such as 3H and 14C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., 3H, and carbon-14, i.e., 14C, isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium, i.e., 2H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. Isotopically labelled compounds of Formula I of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples and Preparations below, by substituting a readily available isotopically labelled reagent for a non-isotopically labelled reagent.
  • Each of the patents, patent applications, published International applications, and scientific publications referred to in this patent application is incorporated herein by reference in its entirety.
    • DETAILED DESCRIPTION OF THE INVENTION
  • General synthetic methods which may be referred to for preparing the compounds of formula I are provided in U.S. Pat. No. 5,990,146 (issued Nov. 23, 1999) (Warner-Lambert Co.) and PCT published application numbers WO 99/16755 (published Apr. 8, 1999) (Merck & Co.) and WO 01140217 (published Jul. 7, 2001) (Pfizer, Inc.).
  • Compounds of the formula I may also be prepared according to the following reaction scheme and discussion. Unless otherwise indicated, R1, R2, R3 and R4 in the reaction scheme and discussion that follow are as defined above.
    Figure US20070088032A1-20070419-C00009
  • With reference to Scheme I above, the compond of formula I may be prepared starting with the palladium amination of reaction of a 2chloro-8-benzyloxyquinoline (VIII) and an appropriate 2-amino-nitrobenzene (VII) to provide the quinoline (VI). Reduction of the nitro group and removal of the benzyl group via cataytic hydrogenation, followed by addition of formamidine acetate provides the benzimidazole (V) which can then be transformed into the corresponding trifiate (IV). A second palladium catalyzed amination With amine (III) provides piperidinyl quinoline (II) and subsequent removal of the t-butoxycarbonyl group provides (I).
  • While not wishing to be bound by theory, the presently claimed process for the preparation of the compounds of formula I from the compounds of formula II under basic (alkaline) conditions is believed to proceed through an isocyanate intermediate (IX) that results from the deprofonation (of the NH proton) of (II) followed by elimination of the t-butoxy group. Hydrolysis of the isocyanate (IX) is believed to produce a carbamic acid (X), which undergoes decarboxylation to produce (I). This mechanism is illustrated in Scheme 2 below. The presence of water as a reactant can be explained by this mechanism.
    Figure US20070088032A1-20070419-C00010
  • The reaction of the compound of formula VIII with the compound of formula VII in the presence of palladium acetate and DIPHOS (1, 2-Bis(diphenylphosphino)ethane} to produce the compound of formula VI is particularly and unexpectedly advantageous compared to the same reaction using palladium acetate, BINAP and PhB(OH)2. The reaction in the presence of DIPHOS results in higher (e.g., 5-25% higher) yields of the product and takes less time to go to completion, particularly in high scale (e.g., 100 grams and higher) synthesis. This process has significant commercial advantages for the production of active ingredients for use in the preparation of a drug.
  • The starting materials employed in Scheme 1 are readily commercially available or readily prepared using methods well known to those of ordinary skill in the art.
  • In each of the reactions discussed or illustrated in the Schemes, pressure is not critical unless otherwise indicated. Pressures from about 0.5 atmospheres to about 5 atmospheres are generally acceptable, and ambient pressure i.e., about 1 atmosphere, is preferred as a matter of convenience.
  • The examples and preparations provided below further illustrate and exemplify the compounds of the present invention, methods of preparing such compounds, and the methods of the present invention. It is to be understood that the scope of the present invention is not limited in any way by the scope of the following examples and preparations. In the following examples molecules with a single chiral center, unless otherwise noted, exist as a racemic mixture. Those molecules with two or more chiral centers, unless otherwise noted, exist as a racemic mixture of diastereomers. Single enantiomers/diastereomers may be obtained by methods known to those skilled in the art.
  • Where HPLC chromatography is referred to in the preparations and examples below, the general conditions used, unless otherwise indicated, are as follows. The column used is a ZORBAX RXC18 column (manufactured by Hewlett Packard) of 150 mm distance and 4.6 mm interior diameter. The samples are run on a Hewlett Packard-1100 system. A gradient solvent method is used running 100 percent ammonium acetate/acetic acid buffer (0.2 M) to 100 percent acetonitrile over 10 minutes. The system then proceeds on a wash cycle with 100 percent acetonitrile for 1.5 minutes and then 100 percent buffer solution for 3 minutes. The flow rate over this period is a constant 3 mL/minute.
  • The present invention is illustrated by the following Examples. It will be understood, however, that the invention is not limited by the specific details of the following Examples.
    • EXAMPLE 1
  • Preparation of 4-(3-Methyl-oxetan-3-ylmethoxy)-2-nitro-phenylamine
    Figure US20070088032A1-20070419-C00011
  • The compound, 3-methyl-3-oxetanemethanol (468 g, 45.8 mmoml. 1.05 equivalent), acetonitnrle (25 mL, 5 volumes), and triethylamine (6.7 mL, 48 mmol, 1.1 equivalent) were charged to a 100 mL round bottomed flask and then cooled to 5-15° C. Methanesulfonyl chloride (3.4 mL, 43.6 mmol, 1.0 equivalent) was charged at a rate which kept the temperature below 45° C. The mixture was stirred at 15-20° C. for 2-6 hours, then cooled to 0-5° C. The solids were filtered through a pad of Celite, then the flask and the filter cake were washed once with 10 mL of acetonitrile. Thereafter, 4-amino-nitophenol (6.73 g 43.6 mmol 1 equivalent) and cesium carbonate (18.5 g, 56.7 mmol, 1.3 equivalents) were charged to the filtrate and the mixture was heated at 45-60° C. for 24 h. Upon reaction completion, ethyl acetate 30 mL, 6 volumes) was charged to the flask. The mixture was stirred for 15-60 min at 35-40° C., and then filtered at 35-40° C. through a pad of Celite. The flask and the filter cake were rinsed with 2 by 6 volumes of ethyl acetate. The filtrate was then washed with 25 volumes of 0.5 N sodium hydroxide solution, followed by 25 volumes of saturated sodium chloride solution. The resulting solution was concentrated to low volume and isopropanol (25 mL, 5 volumes) was added. The solids were granulated at 20-25° C. for at least 10 hours and then collected and dried under vacuum at 40° C. with a slight nitrogen bleed to provide 7.7 g of a reddish orange fluffy solid (74% yield). 1H NMR (d6-DMSO): δ 741 (d, 1H, J=2.9 Hz), 7.29 (br s, 2H), 7.18 (dd, 1H, J=9.1, 2.9 Hz), 6.98 (d, 1H, J=9.1 Hz), 4.46 (d, 2H, J=5.8 Hz), 4.26 (d, 2H, J=5.8 Hz), 3,98 (S, 2H), 1.32 (s, 3H).
    • EXAMPLE 2
  • Preparation of (8-Benzyloxy-quinolin-2-yl)-[4-(3-methyl-oxetan-3-ylmethoxy)-2-nitro-phenyl]-amine
    Figure US20070088032A1-20070419-C00012
  • The compound, 8-Benzyoxy-quinolin-2-ol (5 g, 18.5 m,mol, 1.0 equivalent), 4-(3-Methyl-oxetan-3-ylmethoxy)-2-nitro-phenylamine (5.3 g, 22.2 mmol, 1,2 equivalents), cesium carbonate (8.46 g, 26 mmol, 1.4 equivalents), DIPHOS (1, 2-Bis(diphenylphosphino)ethane; 443 mg, 111 μmol, 0.06 equivalents) and toluene (75 mL, 15 volumes) were charged to a 100 mL round bottom flask. The reaction was deoxygenated. Palladium acetate (83 mg, 37 μmol, 0.02 equivalents) was added and the reaction was deoxygenated again. The reaction was heated to 100° C. for 24-30 hours. At reaction completion, the reaction was cooled to 55° C. and dichloroethane (“DCE”; 75 mL, 15 volumes) was charged. The slurry was filtered through a pad of Celite and then the flask and filter were rinsed once with additional DOCE (50 mL, 10 volumes). The oranics were concentrated to low volume and ethyl acetate (50 mL, 10 volumes) was added. The reaction was heated to reflux and allowed to cool to 20-25° C. The solids were granulated for 10-20 hours, filtered, and dried under vacuum at 40° C. with a slight nitrogen bleed to yield 6.72 g (8-Benxoxy-quinolin-2-yl)-[4-(3-methy-oxetan3ylmethoxy)-2-nitro-phenyl]-amine as an orange solid (77% yield). The material was judged to be about 95% pure by NMR, with ˜5% of the DIPHOS bis-oxide.
  • 1H NMR (d6-DMSO): δ 9.78 (s, 1H), 8.73 (d, 1H, J=9.1 Hz), 8.11 (d, 1H, J=8.7 Hz), 7.55 (m, 2H), 7,36 (m, 4H), 7.22 (m, 4H) 5.20 (s, 2H), 452 (d, 2H, J=5.8 Hz), 4.34 (d, 2H, J =5.8 Hz), 4.12 (s, 2H), 1.40 (s, 3H).
    • EXAMPLE 3
  • Preparation of 2-[5-(3-Methyl-oxetan-3-ylmethoxy)-benzoimidazol-1-yl]quinolin-8ol
    Figure US20070088032A1-20070419-C00013
    phenyl]-amine (5 g, 10.6 mmol, 1,0 equivalent), ethanol (50 mL, 10 volumes), triethylamine (7.8 mL, 56.2 mmol, 5.3 equivalents), and palladium hydroxide on carbon (500 mg, 0.1 weight equivalents) were charged to a 100 mL round bottom flask. The solution was deoxygenated and then heated to 50° C. Once the reaction reached 50° C., formic acid (2,2 ml, 56.2 mmol, 5.3 equivalents) was charged slowly to control any exotherm or off-gasing. The reaction was then heated at 55° C. for 15-25 hours. After nitro group reduction and benzyl group removal was noted by APCI MS, the reaction was cooled to 40° C. and filtered through a pad of Celite. The flask and the filter cake were washed once with ethanol (2.5 volumes). The filtrate was then charged to another 100 mL round bottom flask containing form amdine acetate (2.3 g, 22.3 mmol, 2.1 equivalents) and the reaction was heated at reflux for ˜8 hours. At reaction completion, the reaction was cooled to 20-25° C. and allowed to granulate for 10-20 hours. The solids were isolated by filtration and dried under vacuum at 40° C. with a slight nitrogen bleed to afford 3.14 g of 2-[5-(3-Methyl-oxetan-3-ylmethoxy)-benzoimidazol-1-yl]-quinolin-8-ol as a yellow solid (82% yield). 1H NMR {d6-DMSO): δ 9.88 (s, 1H), 9.25 (s, 1H), 8.61 (d, 1H, J=9.1 Hz), 8.51 (d, 1H, J=9,1 Hz), 8.10 (d, 1H, J=9.1 Hz), 7.44 (m, 2H). 7.35 (d, 1H, J=2.5 Hz), 7.18 (dd, 1H, J=7.5, 1.7 Hz), 7.08(dd, 1H, J=8.7, 2.5Hz), 4.51 (d, 2H, J=5.38 Hz),4.31 (d, 2H, J=5.8 Hz), 4.12 (s, 2H), 1.39 (s, 3H).
    • EXAMPLE4
  • Preparation of Trifluoro-methanesulfonic acid 2-[5-(3-methyl-oxetan-3-ylmethoxy)-benzoimidazol-1-yl]-quinolin-8-yl ester
    Figure US20070088032A1-20070419-C00014
  • N-Phenyftrifluoromethanesulfonimide (PhN(Tf)2, 2.72 g, 7.6 mmol, 1.1 equivalents), 2-[5-(3-Methyl-oxetan-3-ylmethoxy)-benzoimidazol-1-yl]-)quinolin-8-ol (2.5 g, 6.9 mmol, 1.0 equivalent), DMF (7.5 mL, 3 volumes), and then triethylamine (1.9 mL, 13.8 mmol, 2.0 equivalents) were charged to a 50 mL round bottom flask. The slurry was stirred at 20-30° C. for 20-10 hours. After the stirring period, the reaction was filtered and washed with DMF (2.5 mL, 1 volume), followed by isopropy ether (5 mL, 2 volumes) to yield, after drying under vacuum at 40° C. with a slight nitrogen bleed, 2.9 g trifluoro-methanesulfonic acid 2-[5-(3-methy-oxetan-3-ylmethoxy)-benzoimidazol-1-yl]quinolin-8-yl ester as an off-white solid (85% yield).
  • 1H NMR (48-DMSO): δ 9,18 (s 1H), 8.75 (d, 1H, J=9.1 Hz), 8.65 (d, 1H, J=8.7 Hz), 8.33 (d, 1H, J=9.1 Hz), 8.18 (dd, 1H, J=8.3, 1.2 Hz), 7.94 (d, 1H, J=8.9 Hz), 7.70 (t, 1H, J=7.9 Hz), 7.36 (d, 1H, J=2.1 Hz), 7.02 (dd 1H, J=9.1, 2.5 Hz), 4.51 (d, 2H, J=5.8 Hz), 4.31 (d 2H, 4=J5.8 Hz), 4.12 (s, 2H), 1.39 (s, 3H).
    • EXAMPLE 5
  • Preparation of (1-(2-[5-(3-Methyl-oxetan-3-ylmethoxy)-benzoimidazol-1-yl]-quinolin-8-yl}-piperidin-4)-carbamic acid tert-butyl ester
    Figure US20070088032A1-20070419-C00015
  • BiNAP (379 mg, 608 μmol, 0.06 equivalents), tris{dibenzyideneacetone)dipalladium (186 mg, 203 μmol, 0.02 equivalents) and toluene (35 mL, 7 volumes) were added to a 100 mL round bottom flask. The solution was dieoxygenated and stirred at 20-25° C. for ˜30 minutes. Next, trlfluoro-methanesulfonic acid 2-[-(3-methyxl-oxetan-3-ylmethoxy)-benzoimidazol-1-yl}-quinolin-8-yl ester (5 g, 10.1 mmol, 1 equivalent), piperidin-4yl-carbamic acid tert-butyl ester (4.06 g 20.3 mmol, 2.0 equivalents), and cesium carbonate (4.62 g 1.42 mmol, 1.3 equivalents) were charged. The reaction was again deoxygenated and then heated to 85° C. for 24-32 hours. At reaction completion, the reaction was cooled to 30° C. and dichloroethane (5 volumes) and Celite (0.5 wt. equivalent) were added. The slurry was filtered through a pad of Celite and rinsed with dichloroethane (5 volumes). The mother liquor was then concentrated to low volume and ethyl acetate (75 mL, 15 volumes) was charged. The thin slurry was granulated at 20-25° C. for 8-15 h and then filtered. The mother liquor was collected and washed with a 2.5% NaH2PO4 solution (3×9 volumes). The organics were again concentrated to low volume and acetonitrile (25 mL, 5 volumes) was charged. The slurry was granulated for 10-20 hours, and then the solids were filtered and dried under vacuum at 40° C. wth a slight nitrogen bleed to yield 4.33 g (1-(2-[5-(3-Methyl-oxetan-3-ylmethoxy)benzoimidazol-1-yl-quinolin-8-yl,-piperidin4-yl)-carbamic acid tert-butyl ester as a yellow solid (79% yield).
  • 1H NMR (d6-DMSO) δ 9.17 (s, 1H), 8.89 (d, 1H, J=8.7 Hz), 8.51 (d, 1H, J=9.1 Hz), 8.15 (d, 1H, J=9.1 Hz), 7.59 (d, 1, J=8.3 Hz), 7.47 (t, 1H, J=7.9 Hz), 7.35 (m 2H), 7,29 (m, 1H), 7.14 (d, 1H, J=8.3 Hz), 4.54 (d, 2H, J=5.4 Hz), 4.32 (d, 2H, J=5.8 Hz), 4.13 (s, 2HR) 3.75 (d, 2H, J=11.6 Hz), 3.45 (m, 1H), 2.75 (m, 2H), 1.84 (m, 4H), 1.40 (s, 3H), 1.39 (s, 9H).
    • EXAMPLE 6
  • Preparation of 1-{2-[5-(3-Methyl-oxetan-3-ylmethoxy)-benzoimidazzol-1-yl)-quinolin-8-yl}-piperidin-4-ylamine
    Figure US20070088032A1-20070419-C00016
  • The comnpound, (1-{2-[5-(3-Methyl-oxetan-3-ylmethoxy)-benzoimidazol-1-yl]-quinolin 8-yl}-piperidin-4-l)-carbamic acid tert-butyt ester (2 g, 3.68 mmol, 1 equivalent), sodium t-butoxide (1.77 g, 18.4 mmol, 5 equivalents), 2-methyltetrahydrofuran (30 mL, 15 volumes), and water (66 mL, 1 equivalent) were added to a 100 mL round bottom flask. The mixture was heated to reflux and held at reflux for 24-30 hours. At reaction completion, the mixture was cooled to 20-30° C., The reaction was quenched into a 20% citric acid solution (10 volumes) and stirred at 20-30° C. for 30-60 minutes. The citrate salt precipitated out of solution during this time. A 50% sodium hydroxide solution (˜1 weight equivalent) was charged to basify the reaction mixture (pH 10-12). The layers were separated at 30-40° C. The aqueous layer was washed with ethyl acetate (10 volumes) and then the combined organic were concentrated to low volume. Ethyl acetate (14 mL, 7 volumes) was charged and the slurry was allowed to granulate for 10-20 hours. The solids were filtered and 1 -(2-[5-(3-Methyl-oxetan-3-ylmethoxy)-benzoimidazol-1-yl]quinolin-8-yl)piperidin-4-ylamine (1. 4 g 86% yield) was isolated.
  • 1H NMR (d6-DMSO): δ 9.17 (s, 1H), 8.88 (d. 1H, J=8.7 Hz), 8.51 (d, 1H J=9.1 Hz), 8.14 (d, 1H, J=9.1 Hz), 7.57 (d, 1H, J=7.5 Hz), 7.46 (t 1H, J=7.9 Hz), 7.37 (d, 1H, J=2.5 Hz), 7.26 (d, 1H, J=7.9 Hz), 7.15 (dd 1HJ=9.1, 2.5 Hz), 4.53 (,d, 2H, J=5.8 Hz), 4.31 (d, 2H, J=5.8 Hz), 4.13 (s, 2H), 3.71 (d, 2H, J=10.4 Hz), 2.73 (m, 3H), 1.87 (d, 2H, J=11.4 Hz), 1.77 (m, 2H), 1.39 (s, 3H).
    • EXAMPLE 7
  • Preparation of 1-{2-[5-(3-Methyl-oxetan-3-ylmethoxy)-benzoimidazol-1-yl]-quinolin-8-yl}-piperidin-4-ylamine benzensulfonate
    Figure US20070088032A1-20070419-C00017
  • The compound, 1-2-[5-(3-Methoxy-oxetan-3-ylmethoxy)-benzoimidazol-1-yl]-quinolin-8-yl)-piperidin-4-ylamine (2.44 g, 5.5 mmnol, 1 equivalent) and ethanol (24 mL, 10 volumes) were added to a 100 mL round bottom flask. The solution was heated to reflux to dissolve the starting material and then cooled to room temperature. A solution of benzenesulfonic acid (918 mg, 5.2 mmol, 0.95 equivalents) in ethanol (5 mL, 2 volumes) was charged and the reaction was heated to refliux for ˜30 minutes. The reaction was cooled to 20-30° C. and allowed to granulate for 16-32 hours. The material was then filtered and dried under vacuum with a slight nitrogen bleed to afford 1-{2-[5-(3-Methy-oxetan-3-ylmethoxy)-benzoimidazol-1-yl]-quinolin-8-)}-piperidin-4-ylamine benzenesulfonate (2.8 g, 85% yield) as an off-white solid,
  • 1H NMR (d6-DMSO): δ 9.19 (s, 1H), 8.87 (d, 1H, J=9.1 Hz), 8.54 (d, 1H, J=9.1 Hz), 8.16 (d 1H, J=9.1 Hz), 7.94 (br S, 3H), 7.63 (d, 1H J=75 Hz), 7.56 (m 2H), 7.48 (t, 1H, J=7.9 Hz), 7.39 (d 1H, J=2.5 Hz), 7.26 (m, 5H), 4.53 (d, 2H, J=5.8 Hz), 4.31 (d, 2H, J=5.8 Hz), 4.12 (s, 2H), 3.83 (m, 2H), 3.2 (m, 1H), 2.78 (m, 2H), 2.05 (m, 2H), 1.95 (m, 2H), 1.39 (s, 3H).

Claims (15)

1.-40. (canceled)
41. A process for preparing a compound of formula VI
Figure US20070088032A1-20070419-C00018
wherein Bn is benzyi;.
wherein each R1, R2, and R3 is independently selected from the group consisting of H, (C1-C6)alkyl, C3-C6)cycloalkyl, halo, cyano, CF3, difluoromethoxy, trituoromethoxy, —O(C1-C6)alkyl, —O(C3-C6)cycloalkyl, and —NR12R13;
wherein R4 is —(CR5R6)mH or —(CR7R8)n(4 to 10membered)-aromatic or non-aromatic heterocyclic, wherein m is an integer rangng from 1 to 5, wherein n is an integer ranging from 0 to 5 wherein said 4 to 10 membered heterocyclic when aromatic is optionally substituted by 1 to 3 R11 substituents, and wherein said 4 to 10 membered heterocyclic wnen non-aromatic is opotionally substituted by 1 to 3 R10 substituents at any position and optionally subtstituted by 1 to 3 R11 substituents at any position not adacent to or directly attached to a heteroatom;
wherein each R5, R6, R7 and R8 is independently selected froml the group consisting of H and (C1-C6)alkyl;
wherein each R9 is independently selected from H, (C1-C6)alkyl, (C3-C6)cycloalkyl, halo, cyano, CF3, difluoromethoxy, trifluoromethoxy, —O(C1-C6)alkyl, —O(C1-C6)cycloalkyl, and —NR14R15;
wherein each R10 is independently selected from H, (C1-C6)alkyl, and (C3-C6)cycloalkyl;
wherein each R11 is independently selected from halo, cyano, CF3, difluoromethoxy, trifluoromethoxy; —O(C1-C6)alkyl, —O(C3-C6)cycloalkyl, and —NR16R17;
wherein R12, R13, R14, R15, R16 and R17 are independently selected from the group consisting of H, (C1-C6)alkyl, and (C3-C6)cycloalkyl;
wherein each of the aforesaid (C1-C6)alkyl, (C3-C6)cycloalkyl, —O(C1-C6)alkyl and —O(C3-C6)cycloalkyl substituents wherever they occur may optionally be independently substituted by one to three substituents independently selected from the group consisting of halo cyano, amino, (C1-C6)akylamino, [(C1-C6)alkyl]2-amino, perhalo(C1-C6)alkoxy, (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, hydroxy, and (C1-C6)alkoxy; comprising reacting a compound of formula VII
Figure US20070088032A1-20070419-C00019
wherein R3 and R4 are as defined above for formula VI, with a compound of formula VIII
Figure US20070088032A1-20070419-C00020
wherein R1 and R2 are as defined above for formula VI, in the presence of 1, 2-Bis(diphenylphosphino)ethane, a palladiun catalyst and a base.
42. A process according to claim 41, wherein the palladium catalyst is palladium acetate.
43. A process according to claim 41, wherein the palladium catalyst is tris(dibenzylidene acetone) dipalladium (0).
44. A process according to claim 42, wherein the base is cesiuim carbonate.
45. A process according to claim 42, wherein each R1, R2, and R3 is independently selected from H, (C1-C6)alkyl, and (C3-C6)cycloalkyl, halo, and cyano.
46. A process according to claim 44, wherein R4 is —(CR7R8)n(4 to 10 membered)-non-aromatic heterocyclic, wherein n is an integer from 0 to 1 and wherein said 4 to 10 membered nonaromatic heterocyclic group is optionally substituted by 1 to 3 R10 substituents.
47. A process according to claim 46, wherein said 4 to 10 membered non-aromatic heterocyclic is selected from the group consisting of tetrahydrofuranyl, morpholino and oxetanyl.
48. A process according to claim 47, wherein said 4 to 10 membered non-aromatic heterocyclic is oxetanyl.
49. A process according to claim 41, wherein R1 and R2 are both hydrogen, and the compound of formula VII is a compound of formula VIIA.
Figure US20070088032A1-20070419-C00021
50. A process according to claim 41, wherein the reaction is performed in the presence of an aromatic solvent, an ether or a mixture thereof.
51. A process according to claim 50, wherein the reaction is performed in the presence of an aromatic solvent.
52. A process according to claimn 51, wherein the aromatic solvent is toluene.
53. A process according to claim 41, wherein the reaction is performed at a temperature of ahout 90° C. to about 120° C.
54. A process according to claim 50, wherein the ether is at least one member selected from the group consisting of tetrahydrofuran, dimethoxyethane, dimethylformamide and dioxane.
US11/567,071 2003-06-24 2006-12-05 Processes for the Preparation of Benzoimidazole Derivatives Abandoned US20070088032A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/567,071 US20070088032A1 (en) 2003-06-24 2006-12-05 Processes for the Preparation of Benzoimidazole Derivatives

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48217603P 2003-06-24 2003-06-24
US10/875,030 US7183414B2 (en) 2003-06-24 2004-06-23 Processes for the preparation of benzoimidazole derivatives
US11/567,071 US20070088032A1 (en) 2003-06-24 2006-12-05 Processes for the Preparation of Benzoimidazole Derivatives

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/875,030 Division US7183414B2 (en) 2003-06-24 2004-06-23 Processes for the preparation of benzoimidazole derivatives

Publications (1)

Publication Number Publication Date
US20070088032A1 true US20070088032A1 (en) 2007-04-19

Family

ID=33539339

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/875,030 Expired - Lifetime US7183414B2 (en) 2003-06-24 2004-06-23 Processes for the preparation of benzoimidazole derivatives
US11/567,071 Abandoned US20070088032A1 (en) 2003-06-24 2006-12-05 Processes for the Preparation of Benzoimidazole Derivatives

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/875,030 Expired - Lifetime US7183414B2 (en) 2003-06-24 2004-06-23 Processes for the preparation of benzoimidazole derivatives

Country Status (24)

Country Link
US (2) US7183414B2 (en)
EP (1) EP1641780B1 (en)
JP (1) JP2007516168A (en)
KR (2) KR100787649B1 (en)
CN (1) CN100404530C (en)
AR (1) AR044849A1 (en)
AT (1) ATE414077T1 (en)
AU (1) AU2004249511B2 (en)
BR (1) BRPI0411794A (en)
CA (1) CA2529032C (en)
CL (1) CL2004001470A1 (en)
CO (1) CO5650165A2 (en)
DE (1) DE602004017731D1 (en)
DK (1) DK1641780T3 (en)
ES (1) ES2315663T3 (en)
IL (1) IL172064A (en)
MX (1) MXPA05014203A (en)
NO (1) NO20060376L (en)
NZ (2) NZ543714A (en)
RU (1) RU2323214C2 (en)
SG (1) SG161745A1 (en)
TW (1) TWI294425B (en)
WO (1) WO2004113322A1 (en)
ZA (1) ZA200509253B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022019998A1 (en) * 2020-07-20 2022-01-27 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof
TWI905226B (en) 2020-07-20 2025-11-21 美商安羅格製藥股份有限公司 Crystal forms of crenolanib and methods of use thereof

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0411421D0 (en) * 2004-05-21 2004-06-23 Glaxo Group Ltd Novel compounds
JP2008515872A (en) * 2004-10-07 2008-05-15 ファイザー・プロダクツ・インク Benzimidazole derivatives useful as antiproliferative agents
EP1874772A1 (en) * 2005-04-05 2008-01-09 Pharmacopeia, Inc. Purine and imidazopyridine derivatives for immunosuppression
US7504513B2 (en) 2006-02-27 2009-03-17 Hoffman-La Roche Inc. Thiazolyl-benzimidazoles
US8518952B2 (en) 2008-08-06 2013-08-27 Pfizer Inc. 6 substituted 2-heterocyclylamino pyrazine compounds as CHK-1 inhibitors
EP2379543A2 (en) 2008-12-18 2011-10-26 F. Hoffmann-La Roche AG Thiazolyl-benzimidazoles
CN101993416B (en) * 2009-08-27 2013-09-11 中国科学院上海药物研究所 Quinoline compound and preparation method thereof, medicament combination containing compound and application of compound
KR101738063B1 (en) 2012-09-21 2017-05-19 아로그 파마슈티칼스, 인코퍼레이티드 Method of inhibiting constitutively active phosphorylated flt3 kinase
US11642340B2 (en) 2012-09-26 2023-05-09 Arog Pharmaceuticals, Inc. Method of inhibiting mutant C-KIT
JP6042157B2 (en) 2012-09-26 2016-12-14 アログ・ファーマシューティカルズ・リミテッド・ライアビリティ・カンパニーＡｒｏｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，ＬＬＣ Method for inhibiting mutant C-KIT
US10835525B2 (en) 2012-09-26 2020-11-17 Arog Pharmaceuticals, Inc. Method of inhibiting mutant C-KIT
BR112015016282A2 (en) 2013-01-07 2017-07-11 Arog Pharmaceuticals Inc crenolanib for treatment of mutated flt3 proliferative disorders
US10463658B2 (en) 2013-10-25 2019-11-05 Videra Pharmaceuticals, Llc Method of inhibiting FLT3 kinase
MX2019005008A (en) 2016-11-02 2019-09-10 Arog Pharmaceuticals Inc Crenolanib for treating flt3 mutated proliferative disorders associated mutations.
CN107382983B (en) * 2017-08-24 2020-08-07 扬州市三药制药有限公司 Synthesis method of medicine for treating leukemia
CN107382984B (en) * 2017-08-24 2020-07-10 扬州市三药制药有限公司 Preparation method of medicine for treating leukemia
CN110840893A (en) 2018-12-13 2020-02-28 安罗格制药有限责任公司 Pharmaceutical composition containing clainib and application thereof
CN109678849A (en) * 2019-01-16 2019-04-26 北京悦康科创医药科技股份有限公司 A kind of preparation method of anticancer drug
US11471451B2 (en) 2019-08-19 2022-10-18 Arog Pharmaceuticals, Inc. Uses of crenolanib
CN114702428B (en) * 2019-12-09 2023-11-28 苏州恩华生物医药科技有限公司 Siama-1 receptor inhibitors of the bicyclic structure
JP7769388B2 (en) 2019-12-12 2025-11-13 ティン セラピューティクス，インコーポレイテッド Compositions and methods for preventing and treating hearing loss
JP2023536068A (en) * 2020-07-20 2023-08-23 アログ・ファーマシューティカルズ・インコーポレイテッド CRYSTALLINE FORM OF CRENOLANIB AND METHODS OF USING THE SAME
CA3190172A1 (en) * 2020-08-05 2022-02-10 The General Hospital Corporation Salt inducible kinase inhibitors
US20220079934A1 (en) * 2020-09-17 2022-03-17 Arog Pharmaceuticals, Inc. Crenolanib for treating pain
US11524006B2 (en) 2020-09-17 2022-12-13 Arog Pharmaceuticals, Inc. Crenolanib for treating TRK kinase associated proliferative disorders
US11969420B2 (en) 2020-10-30 2024-04-30 Arog Pharmaceuticals, Inc. Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders
WO2022090547A1 (en) 2020-10-30 2022-05-05 Dsm Ip Assets B.V. Production of carotenoids by fermentation
CN113683594B (en) * 2021-09-07 2022-12-27 曲靖师范学院 Quinoline-benzimidazole salt compound and synthesis method and application thereof
JP2023063189A (en) 2021-10-22 2023-05-09 アログ・ファーマシューティカルズ・インコーポレイテッド Crenolanib for Treating FLT3 Mutant Proliferative Disorders Relapsed/Refractory to Previous Therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020032189A1 (en) * 1997-02-27 2002-03-14 Kaneyoshi Kato Amine compounds, their production and use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897401A (en) * 1987-06-19 1990-01-30 Janssen Pharmaceutical N.V. N-(4-piperidinyl) bicyclic condensed 2-imidazolamine derivatives useful in treating allergic diseases
US5478832A (en) * 1992-05-08 1995-12-26 The Green Cross Corporation Quinoline compounds
UA75055C2 (en) * 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Benzoimidazole derivatives being used as antiproliferative agent, pharmaceutical composition based thereon
KR100481900B1 (en) * 1999-12-10 2005-04-11 후지 샤신 필름 가부시기가이샤 Ink-jet head and printer
AU2001286230A1 (en) * 2000-09-14 2002-03-26 Kaneka Corporation Process for the removal of nitrobenzenesulfonyl
PA8580301A1 (en) * 2002-08-28 2005-05-24 Pfizer Prod Inc NEW BENZOIMIDAZOL DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020032189A1 (en) * 1997-02-27 2002-03-14 Kaneyoshi Kato Amine compounds, their production and use

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022019998A1 (en) * 2020-07-20 2022-01-27 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof
US11713310B2 (en) 2020-07-20 2023-08-01 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof
TWI905226B (en) 2020-07-20 2025-11-21 美商安羅格製藥股份有限公司 Crystal forms of crenolanib and methods of use thereof
US12486256B2 (en) 2023-06-28 2025-12-02 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof

Also Published As

Publication number Publication date
EP1641780A1 (en) 2006-04-05
ATE414077T1 (en) 2008-11-15
ES2315663T3 (en) 2009-04-01
US20050020625A1 (en) 2005-01-27
US7183414B2 (en) 2007-02-27
AU2004249511A1 (en) 2004-12-29
HK1089170A1 (en) 2006-11-24
KR20070092333A (en) 2007-09-12
CO5650165A2 (en) 2006-06-30
DE602004017731D1 (en) 2008-12-24
KR100787649B1 (en) 2007-12-21
NZ543714A (en) 2009-06-26
RU2005138367A (en) 2006-08-10
CL2004001470A1 (en) 2005-05-13
NZ571898A (en) 2010-01-29
AU2004249511B2 (en) 2011-01-20
CA2529032A1 (en) 2004-12-29
RU2323214C2 (en) 2008-04-27
CN100404530C (en) 2008-07-23
CN1809556A (en) 2006-07-26
BRPI0411794A (en) 2006-08-08
TW200517393A (en) 2005-06-01
MXPA05014203A (en) 2006-02-24
EP1641780B1 (en) 2008-11-12
DK1641780T3 (en) 2009-02-02
WO2004113322A1 (en) 2004-12-29
ZA200509253B (en) 2007-01-31
IL172064A (en) 2011-01-31
NO20060376L (en) 2006-01-24
KR20060012033A (en) 2006-02-06
TWI294425B (en) 2008-03-11
CA2529032C (en) 2009-12-22
JP2007516168A (en) 2007-06-21
SG161745A1 (en) 2010-06-29
AR044849A1 (en) 2005-10-05

Similar Documents

Publication Publication Date Title
US20070088032A1 (en) Processes for the Preparation of Benzoimidazole Derivatives
ES2563954T3 (en) Phthalazine derivatives as PARP inhibitors
CA2538265C (en) Process for producing imide compound
ES2209158T3 (en) AMINAS RESOLUTION.
ES2702891T3 (en) Method to produce (R) -1,1,3-Trimethyl-4-aminoindane
US20090082366A1 (en) Deuterium-enriched telaprevir
EP1551803B1 (en) Azabicyclo derivatives as muscarinic receptor antagonists
HUT69702A (en) Heterocyclic amines, pharmaceutical compositions containing them and process for preparing them
WO2012165547A1 (en) Method for manufacturing pyrazole derivative
US7745480B2 (en) Deuterium-enriched atorvastatin
TWI491607B (en) A new method for preparing 4,4'-(1-methyl-1,2-ethandiyl)-bis-(2,6-piperazinedione)
US20080319004A1 (en) Deuterium-enriched clopidogrel
WO2015019239A1 (en) Process for the preparation of 1-(3-methyl-1-phenyl-1h-pyrazol-5-yl)piperazine
US20110212976A1 (en) Deuterium-enriched risperidone
US20090062368A1 (en) Deuterium-enriched sunitinib
SG183256A1 (en) Process for the preparation of 2-(cyclohexylmethyl)-n-{2- [(2s)-1-methylpyrrolidin-2-yl]ethyl}-1, 2, 3, 4- tetrahydroisoquinoline-7-sulfonamide
US8669268B2 (en) Deuterium-enriched prasugrel
US20220220072A1 (en) Method for producing cis-(-) flocinopiperidol
US20090082380A1 (en) Deuterium-enriched rosuvastatin
HK1089170B (en) Processes for the preparation of 1-[(benzoimidazole-1yl) quinolin-8-yl] piperidin-4-ylamine derivatives
US20080299217A1 (en) Deuterium-enriched bifeprunox
CN118619871A (en) A Kv1.3 inhibitor and its preparation method and use
US20090062346A1 (en) Deuterium-enriched tipranavir
US20090062182A1 (en) Deuterium-enriched dalbavancin
US20090075917A1 (en) Deuterium-enriched telithromycin

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION